Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.

Iriyama N, Takahashi H, Hatta Y, Miura K, Kobayashi Y, Kurita D, Hirabayashi Y, Hojo A, Kodaira H, Yagi M, Kiso S, Uchino Y, Nakagawa M, Kusuda M, Kobayashi S, Horikoshi A, Kura Y, Yamazaki T, Sawada U, Takeuchi J.

Oncol Rep. 2013 Feb;29(2):805-11. doi: 10.3892/or.2012.2143. Epub 2012 Nov 15.

PMID:
23166041
2.

Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE.

J Clin Oncol. 2012 Sep 1;30(25):3093-9. doi: 10.1200/JCO.2011.40.2719. Epub 2012 Jul 30.

PMID:
22851556
3.

[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].

Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ.

Ai Zheng. 2004 Aug;23(8):943-6. Chinese.

PMID:
15301720
4.

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.

Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators.

Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4.

PMID:
22770877
5.

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang.

N Engl J Med. 2004 Mar 25;350(13):1287-95.

6.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
7.

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.

Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camós M, Colomo L, Espinosa I, Martínez S, Ribera JM, Martino R, Gutiérrez-García G, Montserrat E, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB).

Ann Oncol. 2008 May;19(5):958-63. doi: 10.1093/annonc/mdn022. Epub 2008 Feb 25.

PMID:
18303032
9.

CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.

Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS.

Leuk Lymphoma. 2003 Jun;44(6):967-71.

PMID:
12854895
10.

IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas.

Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K.

Leuk Lymphoma. 2005 Dec;46(12):1743-8.

PMID:
16263576
12.

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF; Dutch-Belgian Hemato-Oncology Cooperative Group.

J Clin Oncol. 2005 Jun 1;23(16):3793-801. Epub 2005 Apr 4.

PMID:
15809447
13.

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W.

Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9.

14.
15.

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW.

Blood. 2007 Apr 1;109(7):2759-66.

16.

Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.

Gkotzamanidou M, Papadimitriou CA.

Crit Rev Oncol Hematol. 2014 Feb;89(2):248-61. doi: 10.1016/j.critrevonc.2013.08.016. Epub 2013 Sep 8. Review.

PMID:
24075060
17.

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R.

Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25.

PMID:
20738307
18.

[Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].

Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):469-73. Chinese.

PMID:
19950562
19.

Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.

Ahn JS, Yang DH, Jung SH, Chae YS, Sohn SK, Yhim HY, Kwak JY, Lee SR, Kim YK, Kim HJ, Lee JJ.

Ann Hematol. 2013 Jun;92(6):789-97. doi: 10.1007/s00277-013-1685-5. Epub 2013 Jan 29.

PMID:
23358616
20.

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.

Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS.

Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.

PMID:
26861608

Supplemental Content

Support Center